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Abstract
Background Recent studies have suggested that sarcopenia is a prognostic risk indicator of postoperative compli-
cations and predicts survival in cancer patients. The aim of this study is to investigate whether sarcopenia is
associated with postoperative short-term outcome (morbidity and mortality) and long-term survival in patients
undergoing esophagectomy for cancer after neoadjuvant chemoradiotherapy.
Methods All patients who underwent neoadjuvant chemoradiotherapy followed by esophagectomy for cancer, and of
whom an adequate CT scan was available, were included in the current study. The presence of sarcopenia was
defined by CT imaging using cut-off values of the total cross-sectional muscle tissue measured transversely at the
third lumbar level.
Results A total number of 120 patients were eligible for analysis. Almost half of the patients (N = 54, 45 %) were
classified as having sarcopenia; 24 sarcopenic patients (44 %) had overweight and 5 sarcopenic patients (9 %) were
obese. Overall morbidity and mortality rate did not differ significantly between sarcopenic and non-sarcopenic
patients, nor did long-term overall or disease-free survival. Also sarcopenic obesity was not associated with worse
outcome.
Conclusion The presence of sarcopenia was not associated with a negative short- and long-term outcome in this
selected group of esophageal cancer patients after neoadjuvant chemoradiotherapy followed by esophagectomy.
Introduction
The increasing incidence of esophageal cancer is at least
partly due to the rising obesity rates worldwide. Although
there is a direct causality between obesity and the
incidence of esophageal cancer, studies have shown that
BMI is not an independent prognostic factor for short- and
long-term outcomes after esophagectomy [1, 2]. More
recently, the focus of preoperative risk assessment has
shifted towards the concept of frailty. Frailty can be
defined as a syndrome of decreased reserve and resistance
to stressors, resulting from cumulative declines across
multiple physiologic systems, and causing vulnerability to
adverse outcomes [3]. An important feature of the frailty
syndrome is loss of muscle tissue referred to as sarcopenia
[4].
Sarcopenia encompasses the condition of decreased
muscle mass and the loss of function due to muscle wast-
ing. Depletion of skeletal muscle mass can occur in normal,
underweight, or overweight patients, and therefore does not
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equal ordinary weight loss or cachexia. It has been
hypothesized that sarcopenia may reflect a state of pro-
longed catabolism or increased metabolic activity of a
more aggressive tumor biology leading to systemic
inflammation causing muscle wasting and poor postoper-
ative outcome. However, the molecular mechanisms of
sarcopenia remain understood poorly. Sarcopenia is an
important factor in functional compromise as it leads to
less physical activity, which in turn leads to more profound
sarcopenia: a vicious circle to functional decline [5–8].
Several studies have examined the relationship between
cancer and sarcopenia. A recent review investigating core
muscle size measured with abdominal CT scans and out-
come after major abdominal surgery suggested that this
assessment is an objective and robust prognostic risk
indicator of postoperative complications and mortality [9].
Furthermore, sarcopenia appeared to be an independent
predictor of worse survival in selected patients with hep-
atocellular, pancreatic, and colorectal carcinoma [10–12].
Nevertheless, body composition has received only minor
attention in risk analysis for esophageal cancer resection
thus far. The aim of the present study is to investigate
whether sarcopenia is of prognostic value with regard to
postoperative short-term outcome (morbidity and mortal-
ity) and long-term survival in patients undergoing
esophagectomy for cancer after neoadjuvant chemoradio-
therapy (nCRT).
Materials and methods
Patient selection and study design
For this study, all patients that took part in the CROSS-I
and CROSS-II trials from 2001 to 2012, as well as patients
treated accordingly after these trials (post-CROSS cohort),
were selected from the institutional database of the Eras-
mus MC. The CROSS-I trial was a single-center non-ran-
domized phase-2 study conducted in the Erasmus MC and
tested the combination of nCRT plus surgery [13]. The
CROSS-II multicenter phase-3 trial randomly assigned
patients to neoadjuvant CRT followed by esophagectomy,
or to surgery alone [14].
Only patients with a CT scan performed not more than 3
months prior to the initial diagnosis of esophageal cancer,
but prior to the start of nCRT, and in which the transverse
circumference of the body at the level of the third lumbar
vertebra was fully visible, were included. In case of mul-
tiple relevant scans prior to the start of nCRT, the most
recent scan was used.
The Medical Ethical Committee of the Erasmus MC had
approved the design of this retrospective study prior to the
start of the data analyses. In the current cohort study, the
principles of the STROBE statement (Strengthening the
Reporting of Observational studies in Epidemiology) have
been applied wherever possible.
Treatments
All patients underwent nCRT, with administration of car-
boplatin and paclitaxel with concurrent radiotherapy for
five weeks [13, 14]. A slight majority of patients underwent
a transthoracic esophagectomy (58 %). Posterolateral tho-
racotomy was the first step in transthoracic resection with
extended lymphadenectomy in the chest. During the tran-
shiatal procedure (38 % of patients), the primary tumor and
its adjacent lymph nodes were dissected under direct vision
through the widened hiatus of the diaphragm up to the level
of the inferior pulmonary vein. In addition, all adjacent
fatty tissue surrounding the tumor was removed simulta-
neously, until the lateral resection margins were reached
(diaphragm, pleura, pericardium, aorta). After mobilization
Fig. 1 a, b. The total cross-sectional transverse area of skeletal
muscles was assessed at the caudal end of the third lumbar vertebra
(highlighted in purple) on a CT scan of both a non-sarcopenic (a) and
a sarcopenic patient (b)
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and transection of the cervical esophagus, the normal
intrathoracic esophagus proximal to the primary tumor was
mobilized bluntly from the neck to the abdomen with a
vein stripper. A gastric tube was created and esopha-
gogastrostomy (hand-sewn or by using a circular stapler)
was performed in the neck. The cervical phase of the
transthoracic procedure was identical to that of the tran-
shiatal procedure. A minority of patients (3 %) underwent
an esophagectomy via a left-sided thoracoabdominal
approach. Tumors were assigned pathologic tumor-node-
metastasis (TNM) stages according to the Union Interna-
tionale Contre le Cancer (UICC) 2002 system (Sixth
edition).
Body composition assessment and analysis
CT scans were used to assess the total cross-sectional
transverse areas (cm2) of skeletal muscles and visceral
Table 1 Clinicopathological characteristics of 120 patients who underwent surgical resection for esophageal cancer after neoadjuvant
chemoradiation
Total
N = 120
Sarcopenia
N = 54
No sarcopenia
N = 66
p value
Agea (years) 62 (19–78) 64 (40–78) 59 (19–78) 0.01
Gender
Male 88 (73 %) 42 (78 %) 46 (70 %) 0.32
Female 32 (27 %) 12 (22 %) 20 (30 %)
ASA classification
I 85 (71 %) 44 (82 %) 41 (62 %) 0.02
II 35 (29 %) 10 (18 %) 25 (38 %)
Operation type
THE 46 (38 %) 19 (35 %)
32 (59 %)
3 (6 %)
27 (41 %)
38 (57 %)
1 (2 %)
0.31
TPL 4 (3 %)
TTE 70 (58 %)
Operation timea (h) 6.5 (3–12) 7.0 (4–12) 6.6 (3–11) 0.30
Histology
Squamous cell carc. 31 (26 %) 16 (30 %) 15 (23 %)
51 (77 %)
0.39
Adenocarcinoma 89 (74 %) 38 (70 %)
Radicalism of resection
R0 110 (92 %) 53 (98 %)
1 (2 %)
57 (86 %)
9 (14 %)
0.02
R1 10 (8 %)
Pathological ypT-category
T0 38 (32 %) 18 (33 %)
8 (15 %)
9 (17 %)
18 (33 %)
1 (2 %)
20 (30 %)
9 (14 %)
13 (20 %)
24 (36 %)
0
0.82
T1 17 (14 %)
T2 22 (18 %)
T3 42 (35 %)
T4 1 (1 %)
Pathological ypN-category
N0 79 (66 %) 38 (70 %)
15 (28 %)
1 (2 %)
0
41 (62 %)
19 (29 %)
3 (5 %)
3 (5 %)
0.33
N1 34 (28 %)
N2 4 (3 %)
N3 3 (3 %)
Number of resected lymph nodesa 17 (4–41) 19 (5–41) 18 (4–39) 0.36
Tumor regression gradeb
Major
Minor
69 (58 %) 33 (61 %)
21 (39 %)
36 (55 %)
30 (45 %)
0.70
51 (43 %)
ASA classification American Society of anesthesiologists classification, THE transhiatal esophagectomy, TPL esophagectomy via left-sided
thoracophrenolaparotomy, TTE transthoracic esophagectomy
a Value presented as median, with its range within brackets
b Tumor regression grade according to the Mandard score: major (Mandard 1–2) or minor (Mandard 3–4) regression
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adipose tissues at the caudal end of the third lumbar ver-
tebra. Cross-sectional measurements of these tissues at the
third lumbar vertebra have been proven to be a good rep-
resentation of the total body composition[15]. Figure 1
shows an example of this cross-sectional measurement in
both a non-sarcopenic (Fig. 1a) and a sarcopenic patient
(Fig. 1b).
Images were analyzed using MeVisLab manual seg-
mentation analysis software (Version 4, MeVis Medical
Solutions AG, Bremen, Germany). The following Houns-
field Units (HU) were used to accurately distinguish
between the different tissues, after manual demarcation of
the general desired area of analysis: -30 to ?150 HU for
skeletal muscle tissue, and -190 to -30 HU for both
subcutaneous- and intramuscular adipose tissue [16].
Manual corrections were applied in cases where fibrous
tissue would otherwise be considered as skeletal muscle
tissue, or where intra-colonic content would be considered
as adipose tissue. At the level of the third lumbar vertebra,
the following skeletal muscles can be identified: rectus
abdominis, external- and internal oblique, transversus
abdominis, psoas major, quadratus lumborum, and erector
spinae (consisting of the iliocostalis and the longissimus
muscles). The classic definition of sarcopenia encompasses
a muscle mass which is two standard deviations below that
typical of a healthy person. Prado et al. have specifically
defined sarcopenia when analyzing patients at the level of
the third lumbar vertebra using CT imaging: sarcopenia is
present if the total cross-sectional muscle tissue measured
transversely at the third lumbar level is less than 52.4 cm2/
m2 body surface area for men and less than 38.5 cm2/m2
body surface area for women [15]. These definitions were
applied to determine whether a patient was sarcopenic or
not.
Statistical analysis
Data were expressed as median values with the range
parenthesized. A binary scoring system was used to cate-
gorically allocate patients based on the presence or absence
of sarcopenia, using the aforementioned reference values
for both sexes. Postoperative complications were graded I
to V based on severity according to the Dindo–Clavien
classification of surgical complications [17] and were
considered categorical data. Differences in outcomes
between these groups were evaluated using non-parametric
tests. Total cross-sectional areas of skeletal muscle and
visceral adipose tissues, and their correlation with short-
and long-term outcome were analyzed. Overall survival
and disease-free survival were depicted through the
Kaplan–Meier method, in which the relevant groups were
compared using the log-rank test. Association between
pretreatment factors and overall survival was determined
using univariable Cox regression modeling. Two-sided
p values B0.05 were accepted as statistically significant.
Data were analyzed using SPSS statistical analysis soft-
ware (SPSS Version 19.0, SPSS Inc, Chicago, IL, USA).
Results
All patients who underwent neoadjuvant treatment
according to the CROSS regimen from 2001 to 2012 at the
Erasmus MC (N = 199) were included in the current study
(CROSS-I, CROSS-II, and post-CROSS cohort). In 120 of
these patients, an adequate CT scan was available includ-
ing the complete third lumbar vertebra; all 120 patients
received the complete neoadjuvant chemoradiotherapy
regimen according to CROSS.
Clinicopathological characteristics are described in
Table 1, including surgical data. The 79 excluded patients
did not differ in baseline characteristics from the 120
included patients for whom an adequate CT was available
(data not shown). Median (range) BMI was 26 kg/m2
(15–43 kg/m2). Some 54 patients were classified as having
sarcopenia (45 %). Of these 54 sarcopenic patients, one
patient (2 %) had underweight, 24 patients (44 %) had a
normal weight, 24 patients (44 %) had overweight, and five
patients (9 %) were obese. Sarcopenic patients had a lower
BMI as compared to the non-sarcopenic group: 25 kg/m2
versus 28 kg/m2, respectively (p = 0.001), and were older
(64 vs. 61 years, p = 0.01). Other clinicopathological
characteristics sorted by parameter sarcopenia are dis-
played in Table 1.
Table 2 Short-term outcome after esophagectomy for cancer; com-
plications were graded according to the Dindo–Clavien
classification[17]
Sarcopenia
(N = 54)
No sarcopenia
(N = 66)
p value
Overall morbidity 42 (78 %) 45 (68 %) 0.24
Dindo-Clavien
Grade I 14 (26 %) 10 (15 %) 0.14
Grade II 12 (22 %) 20 (30 %) 0.32
Grade IIIa/IIIb 7/2 (17 %) 3/5 (12 %) 0.48
Grade IVa/IVb 4/0 (7 %) 3/1 (6 %) 0.77
Grade V (mortality) 3 (6 %) 3 (5 %) 0.80
Minor
complications
(Grade I–IIIB)
35 (65 %) 38 (58 %) 0.42
Major
complications
(Grade IVa–V)
7 (13 %) 7 (11 %) 0.69
Median hospital stay 14 days (9–169) 14 days (7–115) 0.65
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Median (range) length of hospital stay was 14 days
(7–169). Overall morbidity and in-hospital mortality rates
were 73 and 5 %, respectively. Short-term outcome in both
sarcopenic and non-sarcopenic patients is shown in
Table 2. Overall morbidity rate did not differ between
sarcopenic (78 %) and non-sarcopenic (68 %) patients
(p = 0.24); also in-hospital mortality was not different
between the two groups: sarcopenia 6 % versus non-sar-
copenia 5 %, p = 0.80. The type of complications (e.g.,
pulmonary or cardiac complications and infections or
anastomotic leakage) did also not differ between the groups
(data not shown). Furthermore, the histopathological clas-
sification of the resection specimen was not different
between both groups, although the radicality of the
resection was significantly more favorable in the sar-
copenic patients (R0-resection =98 vs. 87 % in non-sar-
copenic patients, p = 0.02).
Median (range) follow-up in the current patient group
was 20 months (0–104). Estimated overall five-year sur-
vival was 58 %, whereas disease-specific five-year survival
was 66 %. Disease recurrence was noted in 35 patients
(29 %): the majority of them (32 patients, 91 %) developed
distant metastases. There was no significant difference in
overall survival between the patients with or without sar-
copenia (p = 0.77, Fig. 2) or in disease-free survival
(p = 0.69).
We compared patients with a low/normal BMI versus
the overweight/obese patients in combination with the
No. at risk 0 months 12 months 24 months 36 months 48 months 60 months
Sarcopenia 54 43 24 13 6 5
No sarcopenia 66 55 39 20 12 9
p=0.77
Fig. 2 Overall five-year
survival in relation to
sarcopenia in 120 patients who
underwent surgical resection for
esophageal cancer after
neoadjuvant chemoradiotherapy
Table 3 Short- and long-term outcome of patients according to BMI and sarcopenia
Sarcopenia (N = 54) No sarcopenia (N = 66)
N MORB MORT OS DFS N MORB MORT OS DFS
BMI B25 (N = 45) 25 56 % 12 % 22 m 22 m 20 60 % 0 % 32 m 29 m
BMI[25 (N = 75) 29 55 % 7 % 25 m 23 m 46 54 % 4 % 28 m 26 m
p value NA 0.82 0.52 0.36 0.35 NA 0.67 0.34 0.39 0.41
N number of patients in the specific subgroup,MORB overall morbidity,MORT in-hospital mortality, OS median overall survival in months, DFS
median disease-free survival in months, NA not applicable
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absence or presence of sarcopenia, in an attempt to identify
a subgroup with better or worse outcome after
esophagectomy. Results are displayed in Table 3: no
increased morbidity or mortality could be identified in
sarcopenic patients with overweight or obesity. Finally, we
performed univariable Cox regression analysis of pre-
treatment factors associated with overall survival
(Table 4). None of the tested pretreatment factors, includ-
ing sarcopenia and BMI, were significantly associated with
survival in this cohort.
Discussion
Recently, the impact of specific body compartments (such
as skeletal muscle mass) and their prognostic value in the
pretreatment phase on postoperative complications and
survival has gained interest, mainly due to its modifiable
feature in order to potentially improve short- and long-term
postoperative outcome. Sarcopenia can be assessed rela-
tively easily on a routine CT scan with no additional
patient burden or costs. Also, sarcopenia can be defined by
a precise quantification of skeletal muscle mass.
The present study shows that overall morbidity, mor-
tality, and long-term survival are similar between sar-
copenic and non-sarcopenic patients in our cohort. This is
in line with two previously published studies investigating
the role of sarcopenia in small groups of esophageal cancer
patients that underwent neoadjuvant chemotherapy
[18, 19]. Another study by Sheetz et al. investigated the
role of decreased core muscle size in 166 patients that
underwent nCRT prior to esophagectomy: no significant
association with complications or survival was found [20].
Although the present study could not demonstrate a rela-
tionship between sarcopenic obesity and patients’ outcome
in the present patient cohort, it might represent a clinically
important subgroup of increased risk for worse outcome.
The combination of obesity and low muscle mass may
influence functional status, chemotherapeutic toxicity, and
survival [15]. It may be interesting to perform larger
studies to investigate this specific, potentially dismal sub-
group of patients in more detail.
Several limitations apply to this study. The current
cohort of patients represents a highly selected patient
group, of which the majority participated in a clinical trial
testing the value of nCRT. Together with the exclusion of
patients without adequate CT scans, this undoubtedly has
resulted in a selection bias. Also, the more ‘‘frail’’ patient
will have been selected not to have surgery; thus, the group
selected for surgery (i.e., the population used in the current
study) will be fitter compared with total population of
esophageal cancer patients in the pretreatment phase.
Furthermore, the CT scan, on which the presence or
absence of sarcopenia was based, was made prior to the
start of nCRT; the influence of the neoadjuvant regimen on
the core muscle mass therefore could not be studied. It is
possible that changes in core muscle mass directly
attributable to nCRT may have confounded the present
data. In this light, one can also comment on the interval
between the CT scan pretreatment and surgery, which is
approximately 4 months. It can be hypothesized that short-
term outcome in the postoperative phase may better be
predicted by means of a more recent scan just prior to
surgery. Finally, sarcopenia is only one of the major fea-
tures of the frailty syndrome, but does not fully cover it.
The frailty phenotype can be defined by the presence of
several components besides sarcopenia, such as low
physical activity, poor endurance, and weakness, that have
not been studied currently. Therefore, further exploration
of the frailty syndrome may be of interest in order to
identify the potentially modifiable risk factors during the
preoperative phase.
In conclusion, the presence of sarcopenia was not
associated with a negative short- and long-term outcome in
this selected group of esophageal cancer patients after
neoadjuvant chemoradiotherapy followed by
esophagectomy.
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Table 4 Univariable analysis of pretreatment factors associated with
overall survival in esophageal cancer patients who underwent
neoadjuvant chemoradiotherapy and surgical resection
Pretreatment factors Univariable analysis
HR 95 % CI p value
Age (per decade) 1.09 (0.79–1.52) 0.60
Gender (male vs. female) 1.49 (0.71–3.13) 0.30
ASA classification (I vs. II) 0.82 (0.42–1.59) 0.56
Histology (SCC vs AC) 1.18 (0.59–2.37) 0.63
Clinical N-stage (cN1 vs. cN0) 1.68 (0.82–3.45) 0.15
Sarcopenia (yes vs. no) 0.91 (0.48–1.71) 0.77
BMI (per point) 1.05 (0.98–1.13) 0.15
HR with 95 % CI hazard ratio with 95 % confidence interval, ASA
classification American Society of Anesthesiologists classification,
SCC squamous cell carcinoma, AC adenocarcinoma
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